BX-795

Catalog No.S1274

Molecular Weight(MW): 591.47

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.

Cited by 31 Publications

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Cell, 2019, 176(6):1447-1460

PubMed: 30799039 ( click the link to review the publication )

Nat Immunol, 2019, 20(1):18-28

PubMed: 30510222 ( click the link to review the publication )

Ocul Surf, 2019, 10.1016/j.jtos.2019.11.011

PubMed: 31770600 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(3)

PubMed: 30717477 ( click the link to review the publication )

Cancer Med, 2019, 8(5):2380-2391

PubMed: 30993888 ( click the link to review the publication )

Int Immunopharmacol, 2019, 77:105914

PubMed: 31634789 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):269

PubMed: 29449645 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):747

PubMed: 29970878 ( click the link to review the publication )

J Thromb Haemost, 2018, 16(6):1211-1225

PubMed: 29575487 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Vet Microbiol, 2018, 227:61-68

PubMed: 30473353 ( click the link to review the publication )

Blood Adv, 2018, 2(23):3428-3442

PubMed: 30504235 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(20):11622-11642

PubMed: 28977426 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:169

PubMed: 28529930 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

J Immunol, 2016, 196(5):2272-82

PubMed: 26826240 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Tissue Eng Part A, 2016, 22(17-18):1075-85

PubMed: 27477105 ( click the link to review the publication )

Front Cell Infect Microbiol, 2016, 6:182

PubMed: 28018864 ( click the link to review the publication )
PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

Am J Reprod Immunol, 2016, 76(5):348-357

PubMed: 27613665 ( click the link to review the publication )

J Biomol Screen, 2016, 10.1177/1087057116656314

PubMed: 27358388 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(49):17438-43

PubMed: 25326420 ( click the link to review the publication )

FEBS J, 2014, 281(17):3816-27

PubMed: 25040165 ( click the link to review the publication )

Virology, 2014, 450-451:182-95

PubMed: 24503081 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112014

PubMed: 25390891 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Description

Targets

PDK-1 ^[1] (Cell-free assay)	c-Kit ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	Chk1 ^[1] (Cell-free assay)
6 nM	320 nM	430 nM	510 nM

In vitro

BX-795 effectively blocks PDK1 activity in PC-3 cells, as shown by their ability to block phosphorylation of S6K1, Akt, PKCδ, and GSK3β. BX-795 potently inhibits tumor cell growth on plastic with IC50 of 1.6, 1.4, and 1.9 μM for MDA-468, HCT-116 and MiaPaca cells, respectively. In soft agar, BX-795 displays higher growth inhibition with IC50 of 0.72, and 0.25 μM for MDA-468, and PC-3 cells, respectively. ^[1] In addition, BX-795, as an inhibitor of the TBK1/IKKɛ, blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β. ^[2] In platelet physiological responses, BX795 produces inhibitory effect on 2-MeSADP-induced or collagen-induced aggregation, ATP secretion and thromboxane generation. ^[3]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human MV-4-11 cell	NFX3NYFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYrJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOk45KG6P	NHn6bXpUSU6JRWK=
KRX cells	Ml7iSpVv[3Srb36gZZN{[Xl?	MkfSO{BucW6\|	M4LzbGlvcGmkaYTpc44hd2ZiU2XNU{11[WepZXSgWWxMOSBqdX7rco94diCxcnnnbY4qKGurbnHz[UBld22jaX6g[ZhxemW\|c3XkJIlvKEuUWDDj[YxteyC3c3nu[{BcOzKSXT3nZY1u[S2DVGCgZY5lKG27ZXzpckBj[XOrYzDwdo91\WmwIIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDdibXnudy=>	MXGyOlI4PTZ6MR?=
human NKM-1 cell	M1e4T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIfuWoZKdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjF7NDFOwG0>	MoPZV2FPT0WU
human P30-OHK cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2HTV2lvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7LDDJR\|UxRTBwNEm2OUDPxE1?	NWrqbXo3W0GQR1XS
human YH-13 cell	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2jqXWlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlYzQDh6IN88US=>	NXPoOVFFW0GQR1XS
human LXF-289 cell	NWLQRndRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU4hUUN3ME2wMlY2Pjl\|IN88US=>	MUTTRW5ITVJ?
human BE-13 cell	M1P6[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2nUXWlvcGmkaYTpc44hd2ZiaIXtZY4hSkVvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcxPDd5IN88US=>	NFrETGNUSU6JRWK=
human RS4-11 cell	NX3kZndHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUHJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|I2QTRizszN	M2LUdHNCVkeHUh?=
human A3-KAW cell	NWO0e2IxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXfJcohq[mm2aX;uJI9nKGi3bXHuJGE{NUuDVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|MxPTVizszN	MnflV2FPT0WU
human PA-1 cell	NHjvT\|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUfJcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkiwOFIzKM7:TR?=	Mm[2V2FPT0WU
human ES7 cell	MkHBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEjWSZdKdmirYnn0bY9vKG:oIHj1cYFvKEWVNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuPFM2PjZizszN	M1XUSnNCVkeHUh?=
human ES8 cell	NInIUG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3uzNWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD64OFM{PiEQvF2=	M1TTeXNCVkeHUh?=
human SW982 cell	NXjXSXdzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnyxTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuPVUyOjRizszN	NYT0VZl7W0GQR1XS
human VA-ES-BJ cell	NV\0eI1XT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIHoWHpKdmirYnn0bY9vKG:oIHj1cYFvKF[DLVXTMWJLKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC57OES2O{DPxE1?	MYTTRW5ITVJ?
human 697 cell	NYTuTZU5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mk\qTY5pcWKrdHnvckBw\iCqdX3hckA3QTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkCxOlI{KM7:TR?=	NHzIe2dUSU6JRWK=
human MOLT-4 cell	M13uUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVzJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFMzPDRizszN	NVjzUVQ2W0GQR1XS
human D-283MED cell	NX7NOZVKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXLJcohq[mm2aX;uJI9nKGi3bXHuJGQuOjh\|TVXEJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4xOzl2ODFOoI0>	MmT3V2FPT0WU
human ALL-PO cell	M3L0cmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlG2TY5pcWKrdHnvckBw\iCqdX3hckBCVExvUF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA3ODd\|IN88US=>	Mo\6V2FPT0WU
human NB14 cell	NVXmSFVLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVXJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC2NFgyKM7:TR?=	NGG1PGdUSU6JRWK=
human NTERA-S-cl-D1 cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV\xU\|BIUW6qaXLpeIlwdiCxZjDoeY1idiCQVFXSRU1UNWOuLVSxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4xPzd5NTFOwG0>	M1\2U3NCVkeHUh?=
human BFTC-905 cell	NIrtU2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NELuWGFKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5yOEGwNUDPxE1?	NYD2WYpGW0GQR1XS
human H4 cell	M2LvUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2jsU2lvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkGwNlAyKM7:TR?=	M2\IbHNCVkeHUh?=
human CHP-212 cell	NFSwcopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnjVTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yPDB\|NzFOwG0>	M1nafHNCVkeHUh?=
human A204 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{K2[GlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVU1PjdizszN	MoLZV2FPT0WU
human NB69 cell	M1LwNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1PPT2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVU5PjVizszN	MUXTRW5ITVJ?
human P12-ICHIKAWA cell	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHAyOi2LQ1jJT2FYSSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwMUixO\|Eh\|ryP	M1zJZXNCVkeHUh?=
human L-363 cell	NEHkOHdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVzJcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6xPFE6PyEQvF2=	NWjLRogxW0GQR1XS
human ES5 cell	M3fBZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIXrc4FKdmirYnn0bY9vKG:oIHj1cYFvKEWVNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVk{PTRizszN	NXzNO4F6W0GQR1XS
human CAL-51 cell	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEPSTIRKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjJzNU[g{txO	NVTxW\|ltW0GQR1XS
human NBsusSR cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVfJcohq[mm2aX;uJI9nKGi3bXHuJG5De3W\|U2KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI1PTd6IN88US=>	MlWwV2FPT0WU
human HOP-92 cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXHCb414UW6qaXLpeIlwdiCxZjDoeY1idiCKT2CtPVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ5MkmzJO69VQ>?	MVXTRW5ITVJ?
human DU-4475 cell	NV;NdHFrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NX\PTHVXUW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OUK0OUDPxE1?	NH;sUIVUSU6JRWK=
human LB1047-RCC cell	M4TLWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlfUTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OUK4NUDPxE1?	MlLTV2FPT0WU
human D-566MG cell	NWTDV5pzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Ml7UTY5pcWKrdHnvckBw\iCqdX3hckBFNTV4Nl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{ODR2ODFOwG0>	MoW3V2FPT0WU
human A375 cell	NHzXSFlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2fqVGlvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|A5PThizszN	M3;MXHNCVkeHUh?=
human ATN-1 cell	MnrvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NX;uclU4UW6qaXLpeIlwdiCxZjDoeY1idiCDVF6tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzdzOEWg{txO	MUPTRW5ITVJ?
human M059J cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUW2ZnM1UW6qaXLpeIlwdiCxZjDoeY1idiCPMEW5TkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzd4NUKg{txO	NWLXOG5DW0GQR1XS
human HSC-3 cell	Mli4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1[4b2lvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ1OjB6IN88US=>	MX\TRW5ITVJ?
human DOHH-2 cell	MmXqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFSzc3hKdmirYnn0bY9vKG:oIHj1cYFvKESRSFitNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDV6MUSg{txO	NU\rd\|MyW0GQR1XS
human G-402 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnPwTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOFY2OjVizszN	M3e0XnNCVkeHUh?=
human LC-2-ad cell	MofsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWPJcohq[mm2aX;uJI9nKGi3bXHuJGxENTJvYXSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ4OTN{IN88US=>	MoHGV2FPT0WU
human LOXIMVI cell	NHjwNZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYWz[3Q1UW6qaXLpeIlwdiCxZjDoeY1idiCOT2jJUXZKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53MEW1NkDPxE1?	MYHTRW5ITVJ?
human DK-MG cell	M1HpfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MULJcohq[mm2aX;uJI9nKGi3bXHuJGRMNU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT61O\|I6QCEQvF2=	NVHWW5B7W0GQR1XS
human HOS cell	NYG0doptT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVLoT3VlUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU4OzB7IN88US=>	M{jQRnNCVkeHUh?=
human BHT-101 cell	M{XGdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4HkcWlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTd6N{eg{txO	NXLkUGdKW0GQR1XS
human U-2-OS cell	NUm5SldtT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlWzTY5pcWKrdHnvckBw\iCqdX3hckBWNTJvT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU5QDB4IN88US=>	NEDrNpJUSU6JRWK=
human D-423MG cell	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXzJcohq[mm2aX;uJI9nKGi3bXHuJGQuPDJ\|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYxQDB4IN88US=>	MmLEV2FPT0WU
human AN3-CA cell	Mm\PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVPpN5lyUW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZ\|OUmxJO69VQ>?	NEL5TmtUSU6JRWK=
human TE-11 cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUPIfmxtUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjV{ODFOwG0>	NHX4bVhUSU6JRWK=
human SK-NEP-1 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWXJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU6HUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43PTN5NjFOwG0>	NHrVZmxUSU6JRWK=
human MG-63 cell	MlXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mm[wTY5pcWKrdHnvckBw\iCqdX3hckBOTy14MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOlg2PjdizszN	MoTjV2FPT0WU
human RH-1 cell	Mn\IS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYf6b5g1UW6qaXLpeIlwdiCxZjDoeY1idiCUSD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU44ODJ5NDFOwG0>	M2Pu[3NCVkeHUh?=
human MDA-MB-157 cell	NGnkU4RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVjJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjdzNke0JO69VQ>?	MWrTRW5ITVJ?
human A427 cell	NIS0PVBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXPJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkezOVg6KM7:TR?=	Ml\WV2FPT0WU
human ES1 cell	NIXYfHJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWPJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwN{W0OVEh\|ryP	NYrlVFRyW0GQR1XS
human C32 cell	NXK2XpRjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{nKdWlvcGmkaYTpc44hd2ZiaIXtZY4hSzN{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT63OlM6KM7:TR?=	NFf2emlUSU6JRWK=
human LAMA-84 cell	M{\obmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH;q[oJKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjd4OEeyJO69VQ>?	MXrTRW5ITVJ?
human YKG-1 cell	Mn\uS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3G2NmlvcGmkaYTpc44hd2ZiaIXtZY4hYUuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc4OTJ2IN88US=>	NVjB[mw2W0GQR1XS
human NCI-H1048 cell	MonNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NG\TT5lKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVA1QCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwN{i1NFkh\|ryP	M3fROnNCVkeHUh?=
human KS-1 cell	NG[zR5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUXxOFdpUW6qaXLpeIlwdiCxZjDoeY1idiCNUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45Ojl6IN88US=>	NIPKc5BUSU6JRWK=
human JVM-3 cell	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoPmTY5pcWKrdHnvckBw\iCqdX3hckBLXk1vMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPFY1QTFizszN	NVL2cHlmW0GQR1XS
human GI-ME-N cell	M{njcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHLhc4VKdmirYnn0bY9vKG:oIHj1cYFvKEeLLV3FMW4h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjh4NUOg{txO	M4XzXXNCVkeHUh?=
human GT3TKB cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWjJcohq[mm2aX;uJI9nKGi3bXHuJGdVO1SNQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPFk3PDJizszN	MnG1V2FPT0WU
human CHL-1 cell	NVvFe4NZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1[zWGlvcGmkaYTpc44hd2ZiaIXtZY4hS0iOLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlkzOzd7IN88US=>	NH;DTIhUSU6JRWK=
human CHP-134 cell	NHrs[YhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH[zWJhKdmirYnn0bY9vKG:oIHj1cYFvKEOKUD2xN\|Qh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl2NE[3JO69VQ>?	NH\uWYpUSU6JRWK=
human 8-MG-BA cell	NX3YUG5vT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIi3T2pKdmirYnn0bY9vKG:oIHj1cYFvKDhvTVetRmEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl3N{S0JO69VQ>?	MmLEV2FPT0WU
human HO-1-N-1 cell	NVOyemJ5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGHQ[G5KdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57N{GxO{DPxE1?	Mn[3V2FPT0WU
human SW1088 cell	MoPqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1HaZmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46QTZ5MzFOwG0>	NHn2OJdUSU6JRWK=
human SW48 cell	NV\xT4NZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGOyO2JKdmirYnn0bY9vKG:oIHj1cYFvKFOZNEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlAzODZ5IN88US=>	NVKwbnR{W0GQR1XS
human VM-CUB-1 cell	NFWyUlFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M{\3XmlvcGmkaYTpc44hd2ZiaIXtZY4hXk1vQ2XCMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB2MUG5JO69VQ>?	MXTTRW5ITVJ?
human COLO-800 cell	MlTHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlHCTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODVzM{[g{txO	M3f4cnNCVkeHUh?=
human TI-73 cell	MnPwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEnLVIJKdmirYnn0bY9vKG:oIHj1cYFvKFSLLUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4yOTN7OTFOwG0>	M4LmN3NCVkeHUh?=
human HN cell	NGfGfGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHHkWIlKdmirYnn0bY9vKG:oIHj1cYFvKEiQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6xNlE6QCEQvF2=	NITWVpVUSU6JRWK=
human DB cell	NVrQRlZQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2WyPGlvcGmkaYTpc44hd2ZiaIXtZY4hTEJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkGyOlMyKM7:TR?=	NXnjTIlrW0GQR1XS
human Ca9-22 cell	NF21To5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGPISYVKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOTJ6NEeg{txO	NHHPd\|dUSU6JRWK=
human A549 cell	M1u4bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVfJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkGzPFA5KM7:TR?=	MVzTRW5ITVJ?
human KGN cell	NGju[mFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mo\0TY5pcWKrdHnvckBw\iCqdX3hckBMT05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKyOVk2KM7:TR?=	MUTTRW5ITVJ?
human BCPAP cell	NWrz[ohDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVTJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6yN\|E2QCEQvF2=	Ml3jV2FPT0WU
human Ramos-2G6-4C10 cell	M4LTNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYDJcohq[mm2aX;uJI9nKGi3bXHuJHJidW:\|LULHOk01SzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6yN\|c2QSEQvF2=	NYPXOGpvW0GQR1XS
human OVCAR-5 cell	M1LLT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mkf0TY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zPzd\|NDFOwG0>	MUjTRW5ITVJ?
human KG-1 cell	M3uycmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2XIb2lvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlc4QTJizszN	MlnOV2FPT0WU
human CAKI-1 cell	NGTmeFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEDFWZFKdmirYnn0bY9vKG:oIHj1cYFvKEODS1mtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjhyNUig{txO	MmPsV2FPT0WU
human QIMR-WIL cell	NYWwN\|VNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3jZbGlvcGmkaYTpc44hd2ZiaIXtZY4hWUmPUj3XTWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjJ6N{S0JO69VQ>?	NH:zfppUSU6JRWK=
human SW1710 cell	NFKwS2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUXaUJV2UW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjJ7MUSyJO69VQ>?	MlnuV2FPT0WU
human SK-UT-1 cell	NVLFZllZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MU\Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI6OzN7IN88US=>	M4TPeXNCVkeHUh?=
human IST-SL1 cell	MoTwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1TMSGlvcGmkaYTpc44hd2ZiaIXtZY4hUVOWLWPMNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzJzN{Sg{txO	NYOzdHBPW0GQR1XS
human SW962 cell	M3fQcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{DPS2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlM{PzV5IN88US=>	NHzLRm1USU6JRWK=
human EM-2 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWfJcohq[mm2aX;uJI9nKGi3bXHuJGVONTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkO1N\|M4KM7:TR?=	MoGyV2FPT0WU
human D-263MG cell	NIP0U4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2HaZmlvcGmkaYTpc44hd2ZiaIXtZY4hTC1{NkPNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzh\|Mkeg{txO	MoP2V2FPT0WU
human T98G cell	NH6zXINIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3foSGlvcGmkaYTpc44hd2ZiaIXtZY4hXDl6RzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuN\|g5PTdizszN	NHfpOXlUSU6JRWK=
human CTB-1 cell	NET3NYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn;STY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuN\|k4PjFizszN	MWLTRW5ITVJ?
human Hs-578-T cell	M3HnZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYTJcohq[mm2aX;uJI9nKGi3bXHuJGh{NTV5OD3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41OTV6NzFOwG0>	M2KzRnNCVkeHUh?=
human SF126 cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX\Mc\|dTUW6qaXLpeIlwdiCxZjDoeY1idiCVRkGyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDN4MkGg{txO	NGLzSpFUSU6JRWK=
human NCI-H460 cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{C3N2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi0OlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjR\|OUW1JO69VQ>?	M3i0VXNCVkeHUh?=
human NCI-H1755 cell	M{W2[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe1OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPTRyNEOg{txO	NIf3XlJUSU6JRWK=
human HL-60 cell	NUXSdJZbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3H4TmlvcGmkaYTpc44hd2ZiaIXtZY4hUExvNkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU1OTV7IN88US=>	NIK4eYpUSU6JRWK=
human G-401 cell	NX[0SZpvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWLJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61OlA6QSEQvF2=	NGOyVXdUSU6JRWK=
human AGS cell	M2PRTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{jkeGlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61OlI2PyEQvF2=	NHi4SnhUSU6JRWK=
human HuO9 cell	MkXZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NULP[HJ6UW6qaXLpeIlwdiCxZjDoeY1idiCKdV:5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42PjR3NjFOwG0>	Ml7ZV2FPT0WU
human MFE-280 cell	NF7WcoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUHJcohq[mm2aX;uJI9nKGi3bXHuJG1HTS1{OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU3Pjh4IN88US=>	M4\uOnNCVkeHUh?=
human NCI-H292 cell	MlPPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHnGWJVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53N{eyNkDPxE1?	NFn5OlFUSU6JRWK=
human HuO-3N1 cell	NHTueYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYDIW2J[UW6qaXLpeIlwdiCxZjDoeY1idiCKdV:tN24yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54MEOwO{DPxE1?	MV7TRW5ITVJ?
human ES3 cell	NHjl[\|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUf5bWJpUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYzOjh3IN88US=>	M4DM[XNCVkeHUh?=
human LB2241-RCC cell	NVvQWpdpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFzFfZBKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkK0NU1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[5NFc6KM7:TR?=	MoDwV2FPT0WU
human NCI-H1155 cell	NW\jeZBiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUPKPZVGUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFEyPTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[5OFA2KM7:TR?=	MXnTRW5ITVJ?
human SW872 cell	M{W5eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEL3ZWxKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44ODZ5NjFOwG0>	MXvTRW5ITVJ?
human MHH-ES-1 cell	M3PMb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIr0bnVKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55Mk[zN{DPxE1?	M4r5[XNCVkeHUh?=
human KYSE-150 cell	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVPYXlhJUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwN{K5O{DPxE1?	MX\TRW5ITVJ?
human MC-IXC cell	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml;QTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg6PTNizszN	MkG2V2FPT0WU
human HCC1187 cell	NE\ubJFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVvs[Hp4UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxNVg4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi56OU[3O{DPxE1?	Mn;OV2FPT0WU
human UMC-11 cell	NW\TenRkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXq1XI5KUW6qaXLpeIlwdiCxZjDoeY1idiCXTVOtNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjlyNEe3JO69VQ>?	MV\TRW5ITVJ?
human NB5 cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkO0TY5pcWKrdHnvckBw\iCqdX3hckBPSjViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmzO\|E2KM7:TR?=	Ml\6V2FPT0WU
human A2058 cell	NHrxb4NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NULWNItxUW6qaXLpeIlwdiCxZjDoeY1idiCDMkC1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTd6NESg{txO	NEPIcpdUSU6JRWK=
human Becker cell	NXT0e2xsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{jM[2lvcGmkaYTpc44hd2ZiaIXtZY4hSmWla3XyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOTFzMjFOwG0>	M{TCdnNCVkeHUh?=
human CAS-1 cell	M1ezN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVexd29EUW6qaXLpeIlwdiCxZjDoeY1idiCFQWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODF3Nkmg{txO	MmHNV2FPT0WU
human SW780 cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnjyTY5pcWKrdHnvckBw\iCqdX3hckBUXzd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuNlU3ODlizszN	MWDTRW5ITVJ?
human KM12 cell	M3PrOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlPDTY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6zNFE{OiEQvF2=	MVrTRW5ITVJ?
human PC-3 cell	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGHF[41KdmirYnn0bY9vKG:oIHj1cYFvKFCFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE4PDFzIN88US=>	Mle2V2FPT0WU
human A253 cell	M2DkU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXjxXVduUW6qaXLpeIlwdiCxZjDoeY1idiCDMkWzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yQDh7MzFOwG0>	NWjEOoJ2W0GQR1XS
human NB10 cell	M2iwTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M13CeGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNlI4PzNizszN	NVH3N4E{W0GQR1XS
human A172 cell	M3XVeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGf0[mZKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ1PTdizszN	NEXVUIpUSU6JRWK=
human A498 cell	M4L0W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M17BUGlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuOVY{QDNizszN	M4jTdnNCVkeHUh?=
human SW1573 cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3X4UWlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzNUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46ODR7MTFOwG0>	NX:zb5ZtW0GQR1XS
human 5637 cell	M{C2d2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYrJcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16LkC3PVA1KM7:TR?=	NUT5TY5GW0GQR1XS
human A388 cell	NVqybnRET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NV;CfZdRUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOTN7ODFOwG0>	MUDTRW5ITVJ?
human U251 cell	MmnkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2rkXGlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUK4MlEyPzVizszN	MnnZV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-p38 / p38 / p-JNK / JNK / gD-2 ; PubMed: 28112176 Acta Pharmacol Sin BX-795 inhibition on HSV replication attenuated by overexpression of p38/JNK. HeLa cells with or without JNK1 or p38 overexpression were infected with HSV-2 and total cellular protein was prepared for WB analysis. gD-2, the phosphorylation level of p38 MA䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘 pTBK1 / TBK1 / pPLK1 / PLK1; PubMed: 26772203 Mol Cancer Ther TBK1 mediated activation of the mitotic kinase PLK1. SW210.5 cells were treated with indicated TBK1 inhibitors for 1 hour and then exposed to 50 ng/mL of nocodazole for 18 hours. Western blot detected the signaling change using indicated antibodies, and β䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ	28112176 26772203
Growth inhibition assay	Cell viability ; PubMed: 26772203 Mol Cancer Ther Four SCLC cell lines with no MYC amplification were treated with TBK1 inhibitor BX-795 at the titration concentration. Cell viability was performed by CellTiter Glo 4 days after treatment. The growth curve was constructed by GraphPad Prism 6.	26772203

Protocol

Kinase Assay:^[1]	- Collapse Kinase assays: PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.
Cell Research:^[1]	- Collapse Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells Concentrations: ~10 μM Incubation Time: 72 hours Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates. (Only for Reference)

Kinase Assay:^[1]

- Collapse

Kinase assays:

PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.

Cell Research:^[1]

- Collapse

Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells
Concentrations: ~10 μM
Incubation Time: 72 hours
Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (169.07 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG +2% Tween 80+ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BX-795 SDF

Molecular Weight	591.47
Formula	C₂₃H₂₆IN₇O₂S
CAS No.	702675-74-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you suggest an in vivo formulation of S1274 for animal studies?
Answer:
We recommend to use the vehicle 2% DMSO+30% PEG +2% Tween 80+ddH2O for in vivo study.

PDK Signaling Pathway Map

Related PDK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
OSU-03012 (AR-12)

OSU-03012 (AR-12) is a potent inhibitor of recombinant PDK-1(phosphoinositide-dependent kinase 1) with IC50 of 5 μM in a cell-free assay and 2-fold increase in potency over OSU-02067.

Features:A derivative of celecoxib with 10-fold greater antitumor activity, but lacks celecoxib's COX-2 inhibitory activity.
BX-912

BX912 is a potent and specific PDK1 inhibitor with IC50 of 12 nM, 9- and 105- fold greater selectivity for PDK1 than PKA and PKC in cell-free assays, respectively. In comparison to GSK3β, selectivity for PDK1 is 600-fold.
GSK2334470

GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM in a cell-free assay, with no activity at other close related AGC-kinases.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 31 Publications

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 31 Publications

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)